Management

  • CEO – Erwan CORCUFF (M.Sc.)

Erwan Corcuff has been a research engineer in the group of Prof. J. Di Santo at the Institut Pasteur for 13 years and holds a M.Sc. in Immunology and a M.Sc. in animal bio-experimentation. He has completed extensive training in innovative company management (Challenge+ HEC 2009; EM Lyon 2010; Boston University 2010). As a co-founder of AXENIS, E. Corcuff received several awards, such as the NETVA award in 2010 and the Paris Grand Prize for Innovation in 2012.

 

  • Chairman of the Board – Antoine BERET

Antoine Béret has more than 30 years of biotech entrepreneurship experience in fields such as immunology, oncology and neurology. He co-founded and served as the CEO of the biotech companies Immunotech (founded in 1982) – now a Beckman-Coulter company – and TROPHOS (founded in 1999). In 2000-2002, he served as CEO of TxCell, a cellular therapy start-up in autoimmune diseases. As a co-founder of AXENIS, A. Béret continues to leverage his extensive biotech expertise.

 

  • CSO – Dr. Nicolas LEGRAND (Ph.D.)

Dr. Nicolas Legrand has over 15 years of experience in both academia and industrial settings. In 2002, he obtained his Ph.D. in Immunology from the University Pierre & Marie Curie (Paris, France), under the direction of Prof. Antonio Freitas at the Institut Pasteur (Paris, France). He next managed several humanized mouse model programs, first as a research scientist in the group of Prof. Hergen Spits at the Academic Medical Center of the University of Amsterdam (The Netherlands), and later as a project manager at AIMM Therapeutics (Amsterdam, The Netherlands). He joined AXENIS as Chief Scientific Officer in 2012.

 

  • Scientific advisor – Dr. James P. DI SANTO (Ph.D., M.D.)

Dr. James Di Santo received his M.D. at Cornell University Medical College and his Ph.D. in Immunology at The Sloan-Kettering Institute in New York City. He completed post-doctoral training at the Necker Hospital in Paris under the direction of Prof. Alain Fischer and as an EMBO Fellow at The University of Cologne with Prof. Klaus Rajewsky. After moving to the Institut Pasteur in 1999, Dr. Di Santo was Director of the Immunology Department from 2002 to 2006. He is currently an INSERM director of research and Professor of Immunology at the Institut Pasteur, and heads a mixed INSERM / Pasteur Unit investigating the pathways that generate and regulate a new family of innate lymphoid cells in mice and man, as well as the creation of immunodeficient mouse models (humanized mice) to study human disease pathophysiology. J. Di Santo is a co-founder of AXENIS.